Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 5:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Type 1 Diabetes
Interventions
Victoza, Placebo, Dapagliflozin 10mg Tab
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Buffalo, New York
Completed No phase listed Observational Accepts healthy volunteers

StatStrip Glucose/Ketone Meter System Ketone Evaluation

NCT05118061
Conditions
Diabetes Mellitus, Ketosis, Diabetic
Interventions
Ketone
Diagnostic Test
Lead sponsor
Nova Biomedical
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Medley, Florida
Conditions
Diabetic Ketoacidosis
Interventions
Continuous Glucose Monitoring (CGM), Standard of Care
Device · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Type1diabetes
Interventions
Very low carbohydrate diet, Standard carbohydrate diet
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes
Interventions
Early Glargine, Late Glargine, IV insulin infusion, IV fluid and electrolytes replacement
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Type 2 Diabetes
Interventions
Glipizide, Glipizide and Glargine
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Completed No phase listed Observational

Diabetic Kidney Alarm (DKA) Study

NCT03128229
Conditions
Type 1 Diabetes Mellitus, Diabetic Ketoacidosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
3 Years to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes

NCT03107208
Conditions
Diabetic Ketoacidosis, Type 1 Diabetes Mellitus
Interventions
Glargine, Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)
Drug · Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Years to 18 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of a Non-invasive Brain Compliance Measurement Device

NCT01753921
Conditions
Diabetes, Diabetic Ketoacidosis
Interventions
this is not an intervention study, MRI
Other · Device
Lead sponsor
Stanford University
Other
Eligibility
10 Years to 16 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Completed No phase listed Observational Accepts healthy volunteers

Diabetic Ketoacidosis: Brain Morphology and Cognition

NCT02443415
Conditions
Diabetic Ketoacidosis
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Type 1 Diabetes (T1D), Glycemic Control for Diabetes Mellitus, Insulin, Ketones, Cardiovascular Health
Interventions
CIR-0602K, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Completed Not applicable Interventional Results available

Cerebral Edema in Pediatric Diabetic Ketoacidosis

NCT00629707
Conditions
Diabetic Ketoacidosis
Interventions
intravenous fluid treatment
Other
Lead sponsor
University of California, Davis
Other
Eligibility
8 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Sacramento, California
Conditions
Type 2 Diabetes
Interventions
Empagliflozin 25 MG
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
30 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Not listed No phase listed Observational

DKA Optic Ultrasound

NCT02130180
Conditions
Diabetic Ketoacidosis, Uncontrolled Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
7 Years to 18 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Minneapolis and Saint Paul, Minnesota
Conditions
Type 2 Diabetes
Interventions
Empagliflozin 25 MG, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
30 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions
Arginine hydrochloride, Sodium Chloride 0.9%
Drug
Lead sponsor
David K Carroll
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Type2 Diabetes, Heart Failure With Preserved Ejection Fraction
Interventions
Empagliflozin 25 MG, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Type I Diabetes
Interventions
Anakinra, Placebo Comparator
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Aurora, Colorado
Terminated Not applicable Interventional Results available

Two Bag System for Diabetic Ketoacidosis

NCT03660189
Conditions
Diabetic Ketoacidosis
Interventions
Two bag system
Other
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Diabetic Ketoacidosis
Interventions
Insulin (Aspart Insulin [Novolog], Regular Insulin)
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Completed No phase listed Observational Accepts healthy volunteers

Ketosis Prone Diabetes in African-Americans

NCT00426413
Conditions
Ketosis Prone Diabetes, Diabetic Ketoacidosis, Severe Hyperglycemia
Interventions
pioglitazone
Drug
Lead sponsor
Emory University
Other
Eligibility
19 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Diabetes Mellitus, Type 1, Type 1 Diabetes, Diabetes, Autoimmune, Diabetes type1, Autoimmune Diabetes, Diabetes Mellitus, Brittle, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Insulin-Dependent, 1, Diabetes Mellitus, Juvenile-Onset, Diabetes Mellitus, Ketosis-Prone, Diabetes Mellitus, Sudden-Onset, Insulin-Dependent Diabetes Mellitus 1, Juvenile-Onset Diabetes, Type 1 Diabetes Mellitus
Interventions
Bionic Pancreas, Usual Care
Device · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Conditions
Evaluate Ketogenic Stress
Interventions
Exenatide/Exenatide extended release, Dapagliflozin, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Williamsville, New York
Conditions
Ketosis Prone Diabetes
Interventions
Continuous Glucose Monitoring, Insulin
Device · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia